23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
230 days ago by
Runtime: 1m0s | Views: 5 |
Not yet rated